Vistagen Therapeutics annual revenue
2011
2012
2013
2016
2017
2018
2020
2021
2022
2023
2024
2025
2026
Vistagen Therapeutics Revenue Growth & History (VTGN)
Vistagen Therapeutics reported $1.3M in revenue for fiscal 2026, an increase of 161.11% from the previous fiscal year.
View full Vistagen Therapeutics company overviewVistagen Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.3M | $783,000 | +161.11% |
| 2025 | 2025-03-31 | $486,000 | −$578,000 | −54.32% |
| 2024 | 2024-03-31 | $1.1M | $1.3M | +568.72% |
| 2023 | 2023-03-31 | −$227,000 | −$1.3M | −120.47% |
| 2022 | 2022-03-31 | $1.1M | $19,400 | +1.78% |
| 2021 | 2021-03-31 | $1.1M | $1.1M | — |
| 2020 | 2020-03-31 | $0 | — | — |
| 2018 | 2018-03-31 | $0 | −$1.3M | −100.00% |
| 2017 | 2017-03-31 | $1.3M | $1.3M | — |
| 2016 | 2016-03-31 | $0 | — | — |
| 2013 | 2013-03-31 | $200,400 | −$1.1M | −85.07% |
| 2012 | 2012-03-31 | $1.3M | −$728,800 | −35.19% |
| 2011 | 2011-03-31 | $2.1M | — | — |
Vistagen Therapeutics quarterly revenue
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q3.18
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $1.5M | $1.2M | +504.92% |
| Q4 2026 | 2026-03-31 | $464,000 | $479,000 | +3193.33% |
| Q3 2026 | 2025-12-31 | $303,000 | $69,000 | +29.49% |
| Q2 2026 | 2025-09-30 | $258,000 | $75,000 | +40.98% |
| Q1 2026 | 2025-06-30 | $244,000 | $160,000 | +190.48% |
| Q4 2025 | 2025-03-31 | −$15,000 | −$213,000 | −107.58% |
| Q3 2025 | 2024-12-31 | $234,000 | −$177,000 | −43.07% |
| Q2 2025 | 2024-09-30 | $183,000 | −$95,000 | −34.17% |
| Q1 2025 | 2024-06-30 | $84,000 | −$93,000 | −52.54% |
| Q4 2024 | 2024-03-31 | $198,000 | $22,000 | +12.50% |
| Q3 2024 | 2023-12-31 | $411,000 | $231,000 | +128.33% |
| Q2 2024 | 2023-09-30 | $278,000 | $1.2M | +131.13% |
| Q1 2024 | 2023-06-30 | $177,000 | −$133,100 | −42.92% |
| Q4 2023 | 2023-03-31 | $176,000 | $137,000 | +351.28% |
| Q3 2023 | 2022-12-31 | $180,000 | −$177,900 | −49.71% |
| Q2 2023 | 2022-09-30 | −$893,000 | −$1.3M | −349.44% |
| Q1 2023 | 2022-06-30 | $310,100 | −$44,000 | −12.43% |
| Q4 2022 | 2022-03-31 | $39,000 | −$403,000 | −91.18% |
| Q3 2022 | 2021-12-31 | $357,900 | $44,300 | +14.13% |
| Q2 2022 | 2021-09-30 | $358,000 | $24,000 | +7.19% |
| Q1 2022 | 2021-06-30 | $354,100 | $354,100 | — |
| Q4 2021 | 2021-03-31 | $442,000 | $442,000 | — |
| Q3 2021 | 2020-12-31 | $313,600 | $313,600 | — |
| Q2 2021 | 2020-09-30 | $334,000 | $334,000 | — |
| Q1 2021 | 2020-06-30 | $0 | $0 | — |
| Q4 2020 | 2020-03-31 | $0 | — | — |
| Q3 2020 | 2019-12-31 | $0 | — | — |
| Q2 2020 | 2019-09-30 | $0 | — | — |
| Q1 2020 | 2019-06-30 | $0 | — | — |
| Q3 2018 | 2017-12-31 | $0 | −$1.3M | −100.00% |
| Q4 2017 | 2017-03-31 | $0 | — | — |
| Q3 2017 | 2016-12-31 | $1.3M | $1.3M | — |
| Q2 2017 | 2016-09-30 | $0 | — | — |
| Q1 2017 | 2016-06-30 | $0 | — | — |
| Q3 2016 | 2015-12-31 | $0 | — | — |
| Q4 2013 | 2013-03-31 | $0 | −$469,000 | −100.00% |
| Q3 2013 | 2012-12-31 | $0 | −$2,000 | −100.00% |
| Q2 2013 | 2012-09-30 | $0 | −$316,000 | −100.00% |
| Q1 2013 | 2012-06-30 | $200,400 | −$354,600 | −63.89% |
| Q4 2012 | 2012-03-31 | $469,000 | $116,269 | +32.96% |
| Q3 2012 | 2011-12-31 | $2,000 | −$582,772 | −99.66% |
| Q2 2012 | 2011-09-30 | $316,000 | −$83,576 | −20.92% |
| Q1 2012 | 2011-06-30 | $555,000 | −$178,921 | −24.38% |
| Q4 2011 | 2011-03-31 | $352,731 | — | — |
| Q3 2011 | 2010-12-31 | $584,772 | — | — |
| Q2 2011 | 2010-09-30 | $399,576 | — | — |
| Q1 2011 | 2010-06-30 | $733,921 | — | — |
Vistagen Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $1.1M to $1.3M, a compound annual growth rate of 3.10%. Vistagen Therapeutics's latest reported quarter, Q1 2027, generated $1.5M in revenue, an increase of 504.92% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Vistagen Therapeutics source filings ↗